- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Value of Adherence
Darius Lakdawalla, PhD, addresses the value of diabetes patients' adherence in this clip.
Darius Lakdawalla, PhD, addresses the value of diabetes patients’ adherence in this clip. According to Dr Lakdawalla, diabetes patients account for about one-third of total Medicare spending. By 2050, that percentage could be one half of Medicare spending. Risk factors, including the rise of obesity in the population, are contributing to the increase of diabetes diagnoses.
To control rising costs, Dr Lakdawalla suggests interventions must be made, including biomedical innovation and technologies that can improve medication adherence. Improved adherence could be worth almost $13,000 per patient with diabetes
.
“Some payers have been reluctant to reimburse technologies that focus specifically on adherence and convenience and those kinds of outcomes,” says Dr Lakdawalla. “That's changing with the implementation of the ACA and other kinds of policies in which payers are taking a more holistic role in care. Those changes, I think, are to be encouraged.”
Diabetes Risk Driven by Economic Disparity in Hispanic, Latino Communities
March 28th 2025Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
